KAINOS Laboratories (TSE:4556) Change In Receivables: 円137 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4556 KAINOS Laboratories Inc TSE:4556
47 GF Score
Price 円2,268.00
GF Value 円1,285.89
! 6 Warning Signs
View Full Analysis

What is KAINOS Laboratories Change In Receivables?

KAINOS Laboratories TSE:4556 47 Change In Receivables is 円137 Mil as of Mar. 2026. GuruFocus rates TSE:4556 with a GF Score™ of 47/100 and a GF Value™ of 円1,285.89. The stock has 6 warning signs investors should review.

KAINOS Laboratories's change in receivables for the quarter that ended in Mar. 2026 was 円324 Mil. It means KAINOS Laboratories's Accounts Receivable declined by 円324 Mil from Sep. 2025 to Mar. 2026 .

KAINOS Laboratories's change in receivables for the fiscal year that ended in Mar. 2026 was 円137 Mil. It means KAINOS Laboratories's Accounts Receivable declined by 円137 Mil from Mar. 2025 to Mar. 2026 .

KAINOS Laboratories's Accounts Receivable for the quarter that ended in Mar. 2026 was 円1,264 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. KAINOS Laboratories's Days Sales Outstanding for the six months ended in Mar. 2026 was 85.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. KAINOS Laboratories's liquidation value for the six months ended in Mar. 2026 was 円3,290 Mil.

KAINOS Laboratories  (TSE:4556) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

KAINOS Laboratories's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1264.06/2711.715*91
=85.07

2. In Ben Graham's calculation of liquidation value, KAINOS Laboratories's accounts receivable are only considered to be worth 75% of book value:

KAINOS Laboratories's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4174.23-2328.843+0.75 * 1264.06+0.5 * 992.895
=3,290

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories Change In Receivables Related Terms

KAINOS Laboratories Change In Receivables Historical Data

* Premium members only.

The historical data trend for KAINOS Laboratories's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KAINOS Laboratories Change In Receivables Chart

KAINOS Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -123.51 -78.38 -154.99 168.56 136.74

KAINOS Laboratories Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.56 60.60 107.96 -187.60 324.34
TSE:4556
47GF Score
KAINOS Laboratories Inc TSE:4556
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

KAINOS Laboratories Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円137 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円137 Mil mean?
KAINOS Laboratories (TSE:4556) has a Change In Receivables of 円137 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for KAINOS Laboratories and its competitors.
Is KAINOS Laboratories' Change In Receivables too high?
KAINOS Laboratories' current Change In Receivables is 円137 Mil. Overall, KAINOS Laboratories has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Change In Receivables compare to ISRG and BDX?
KAINOS Laboratories' Change In Receivables of 円137 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for KAINOS Laboratories and its competitors. KAINOS Laboratories's current Change In Receivables is 円137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
KAINOS Laboratories (TSE:4556) has a current Change In Receivables of 円137 Mil. The stock's GF Value™ is 円1,285.89, compared to a current price of 円2,268.00 — trading 76.4% above its estimated fair value. The current Change In Receivables is 円137 Mil. KAINOS Laboratories' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Change In Receivables is 円137 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?

Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued. The current stock price of 円2,268.00 is trading 76.4% above its estimated GF Value™ of 円1,285.89.

Key valuation signals for TSE:4556:

  • Change In Receivables: 円137 Mil
  • GF Value™: 円1,285.89 vs. price of 円2,268.00 (76.4% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

KAINOS Laboratories Business Description

Address 38-18, Hongo 2-chome, Bunkyo-ku, Tokyo, JPN
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
47GF Score

Get the complete analysis for TSE:4556

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,268.00
Price
円1,285.89
GF Value